Radnostix, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 41 full-time employees. The firm manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. The firm provides contract manufacturing of various drug products as well as radioisotope active pharmaceutical ingredient (API) supply for third party theranostics clients. The firm manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and single photon emission computed tomography (SPECT)/positron emission tomography (PET) imaging systems as well as industrial calibration standards under its RadQual brand. The firm also manufactures Cobalt-60 sealed source products.
How did INIS's recent EPS compare to expectations?
The most recent EPS for RADNOSTIX, INC. is $, expectations of $.
How did RADNOSTIX, INC. INIS's revenue perform in the last quarter?
RADNOSTIX, INC. revenue for the last quarter is $
What is the revenue estimate for RADNOSTIX, INC.?
According to of Wall street analyst, the revenue estimate of RADNOSTIX, INC. range from $ to $
What's the earning quality score for RADNOSTIX, INC.?
RADNOSTIX, INC. has a earning quality score of B+/47.822376. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does RADNOSTIX, INC. report earnings?
RADNOSTIX, INC. next earnings report is expected in 2026-02-16
What are RADNOSTIX, INC.'s expected earnings?
RADNOSTIX, INC. expected earnings is $, according to wall-street analysts.
Did RADNOSTIX, INC. beat earnings expectations?
RADNOSTIX, INC. recent earnings of $ expectations.